J. Wanders

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)

Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced Cancer